Abstract:Bo Feng, 1, &ast Xu Dong, 1, &ast Zhen Liu, 2 Jie Zhang, 3 Hongyu Liu, 1 Yuan Xu 1 1 Department of Pharmacy, The Affiliated Hospital of Yangzhou University, Yangzhou, People's Republic of China; 2 Department of Neurology, The Affiliated Hospital of Yangzhou University, Yangzhou, People's Republic of China; 3 Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People's Republic of China &astThese authors contributed equally to this work Correspondence: Hongyu Liu; Yuan Xu, Department of Pharmacy, The Affiliated Hospital of Yangzhou University, Yangzhou, People's Republic of China, Email ; Purpose: Protein tyrosine phosphatases (PTPs) play an essential way in diseases including cancer, obesity, diabetes and autoimmune disorders. As a member of PTPs, low molecular weight PTP (LMPTP) has been a well-recognized anti-insulin resistance target in obesity. However, the number of reported LMPTP inhibitors is limited. Our research aims to discover a novel LMPTP inhibitor and evaluate its biological activity against insulin resistance. Methods: A virtual screening pipeline based on the X-ray co-crystal complex of LMPTP was constructed. Enzyme inhibition assay and cellular bioassay were used to evaluate the activity of screened compounds. Results: The screening pipeline rendered 15 potential hits from Specs chemical library. Enzyme inhibition assay identified compound F9 (AN-465/41163730) as a potential LMPTP inhibitor with a K i value of 21.5 ± 7.3 μM. Cellular bioassay showed F9 could effectively increase the glucose consumption of HepG2 cells as a result of releasing insulin resistance by regulating PI3K-Akt pathway. Conclusion: In summary, this study presents a versatile virtual screening pipeline for potential LMPTP inhibitor discovery and provides a novel-scaffold lead compound that is worthy of further modification to get more potent LMPTP inhibitors. Graphical Keywords: virtual screening, low molecular weight protein tyrosine phosphatase, LMPTP inhibitor, insulin resistance, molecular docking Graphical Protein tyrosine phosphorylation, regulated by protein tyrosine kinases (PTKs) and protein tyrosine phosphatases (PTPs), is essential for numerous cellular processes like cell growth, differentiation, migration and survival. 1,2 Selective modulation of the signaling pathway involved in protein tyrosine phosphorylation has been an effective strategy for therapeutic intervention due to the successful clinical application of various PTK inhibitors. As counterparts of PTKs, PTPs have attracted more attention as the potential therapeutic targets for different diseases, including cancer, 3 obesity, 4 diabetes 5,6 and autoimmune disorders. 7 More than 100 PTPs have been discovered, and most of them share the similar active site sequence C(X)5R(S/T), which specifically binds the phosphoryl group of their substrates. 8,9 Low molecular protein tyrosine phosphatase (LMPTP) is the only member of the Class II subfamily of PTPs besides the recently reclassified SSU72. 10 Abundant studies suggest that LMPTP is a potential target for alleviating insulin resistance in obesity and diabetes. 11,12 LMPTP knockdown by antisense oligonucleotides effectively decreases insulin resistance in diet-induced obese (DIO) mice by enhancing insulin receptor phosphorylation. 13 Given the insulin receptor dephosphorylating function of LMPTP, developing small molecular inhibitors of LMPTP as insulin sensitizers has attracted considerable interest from researchers. 14 However, most reported inhibitors, containing phosphate 15 (Figure 1a), carboxylic 16 (Figure 1b) and sulfonic group 17 (Figure 1c) targeting LMPTP active site exhibit poor selectivity and druggability because of the highly charged and homologous characteristics of LMPTP. 18,19 Hence, developing non-active site inhibitors would be the solution to the problems above-mentioned (Figure 1d and e). 20,21 Figure 1 The representative LMPTP inhibitors. ( a – c ) Representative active site inhibitors of LMPTP; ( d and e ) representative non-active site inhibitors of LMPTP. Herein, a virtual screening pipeline was developed based on the X-ray structure of LMPTP complexes, 20 and a novel LMPTP non-active site inhibitor was identified through this method. Enzyme inhibition assay found that the compound displayed a moderate LMPTP in -Abstract Truncated-

Fast identification of novel lymphoid tyrosine phosphatase inhibitors using target-ligand interaction-based virtual screening.

Identification and Structure-Function Analyses of an Allosteric Inhibitor of the Tyrosine Phosphatase PTPN22.

Structure, inhibitor, and regulatory mechanism of Lyp, a lymphoid-specific tyrosine phosphatase implicated in autoimmune diseases

Substrate Specificity of Lymphoid-specific Tyrosine Phosphatase (Lyp) and Identification of Src Kinase-associated Protein of 55 kDa Homolog (SKAP-HOM) as a Lyp Substrate

Substrate selection influences molecular recognition in a screen for lymphoid tyrosine phosphatase inhibitors

Discovery of benzofuran-2-carboxylic acid derivatives as lymphoid tyrosine phosphatase (LYP) inhibitors for cancer immunotherapy

Protein Flexibility in Docking-Based Virtual Screening: Discovery of Novel Lymphoid-Specific Tyrosine Phosphatase Inhibitors Using Multiple Crystal Structures

Interfering B cell receptor signaling via SHP-1/p-Lyn axis shows therapeutic potential in diffuse large B-cell lymphoma

Identification of potential leukocyte antigen-related protein (PTP-LAR) inhibitors through 3D QSAR pharmacophore-based virtual screening and molecular dynamics simulation

Synthesis and biological evaluation of 2,5-diaryl-1,3,4-oxadiazole derivatives as novel Src homology 2 domain-containing protein tyrosine phosphatase 2 (SHP2) inhibitors

Lead identification of novel and selective TYK2 inhibitors

Repositioning liothyronine for cancer immunotherapy by blocking the interaction of immune checkpoint TIGIT/PVR

Discovery of New Syk Inhibitors Through Structure-Based Virtual Screening.

Virtual Screening and Biological Evaluation of Novel Low Molecular Weight Protein Tyrosine Phosphatase Inhibitor for the Treatment of Insulin Resistance

Identification of Novel Tyrosinase Inhibitors with Nanomolar Potency Using Virtual Screening Approaches

Biochemical and functional studies of lymphoid-specific tyrosine phosphatase (Lyp) variants S201F and R266W.

Identification of novel EZH2 inhibitors through pharmacophore-based virtual screening and biological assays

Design and Biological Evaluation of Novel Imidazolyl Flavonoids As Potent and Selective Protein Tyrosine Phosphatase Inhibitors.

Discovery of Inhibitors Targeting Protein Tyrosine Phosphatase 1B Using a Combined Virtual Screening Approach

A novel highly selective allosteric inhibitor of tyrosine kinase 2 (TYK2) can block inflammation- and autoimmune-related pathways

Discovery of Novel Ligands for TNF-α and TNF Receptor-1 Through Structure-Based Virtual Screening and Biological Assay